InvestorsHub Logo
Post# of 251304
Next 10
Followers 49
Posts 3514
Boards Moderated 0
Alias Born 08/24/2005

Re: poorgradstudent post# 202203

Monday, 06/27/2016 12:59:20 PM

Monday, June 27, 2016 12:59:20 PM

Post# of 251304
SRPT > Third time the charm? Analyst says a marketing decision is “imminent” for Sarepta’s Duchenne drug eteplirsen

http://endpts.com/third-time-the-charm-analyst-says-a-marketing-decision-is-imminent-for-sareptas-duchenne-drug-eteplirsen/

“We believe that right now, someone, whether at Sarepta or the FDA, is looking at baseline and 48-week Western blots for 13 PROMOVI patients,” Skorney noted. “At this point, we think the decision should be pretty cut and dry: if the baseline blots show no band, and the vast majority of the 48-week blots show a (dystrophin) band, we predict a rapid accelerated approval for eteplirsen.”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.